 |
|
Thrombosis Prophylaxis in Cancer Patients With a Central Venous Catheter—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
With their study, Laporte and colleagues address an important question with regard to the prevention of catheter-related thrombosis in patients with cancer.1 Until recently, only 2 prospective randomized controlled trials were available on this subject, and although both found a reduction in catheter-related thrombosis with the use of anticoagulants, no definite overall conclusions could be drawn since they studied different types of thromboprophylaxis (low-dose warfarin and low-molecular-weight heparin).2-3 Therefore, there was a need for a study that compared these 2 types of anticoagulants head-to-head. And this is exactly what Laporte and colleagues did.
In a prospective, randomized open-label study, Laporte and colleagues compared a fixed daily dose of 1 mg of warfarin by mouth with a fixed daily dose of 2850 IU of subcutaneous nadroparin for the prevention of catheter-related thrombosis in patients with a malignancy.1 Additionally, the use of heparin flushes was advised in both patient groups. . . . [Full Text of this Article]
Clara P. W. Klerk, MD;
Harry R. Büller, MD, PhD
Amsterdam, the Netherlands
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Thrombosis Prophylaxis in Cancer Patients With a Central Venous Catheter
Silvy Laporte, Hervé Decousus, and Patrick Mismetti
Arch Intern Med. 2004;164(4):459.
EXTRACT
| FULL TEXT
Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review
Clara P. W. Klerk, Susanne M. Smorenburg, and Harry R. Büller
Arch Intern Med. 2003;163(16):1913-1921.
ABSTRACT
| FULL TEXT
|
